PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.587
https://www.valueinhealthjournal.com/article/S1098-3015(21)00804-4/fulltext
Section Title :
Section Order :
10065
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00804-4&doi=10.1016/j.jval.2021.04.587